Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

The advanced glycation end-products (AGEs) are toxic molecules result from non-enzymatic interactions of sugar with lipids or proteins. AGEs promote the generation of reactive oxygen species that induce the release of pro-inflammatory cytokines, and alter the intracellular signaling leading to progressive biochemical and metabolic derangements. AGEs-induced cellular aging is implicated in the development and progression of different neurological disorders such as dementia, neuropsychiatric disorders, and cerebrovascular diseases. Particularly, AGEs-induced microangiopathy and macroangiopathy trigger the induction of prothrombotic/thrombotic cascades with subsequent increase risk of acute ischemic stroke (AIS). Many studies highlighted that AGEs serum levels are correlated with the incidence, pathogenicity, and severity of AIS. However, the relationship between AGEs and AIS is not elucidated completely. Therefore, this review aims to discuss how AGEs promote the development and progression of AIS, and how AGEs inhibitors could be effective in the management of AIS.

What this study adds

Evidence grade: Low

This review discusses how advanced glycation end-products may contribute to ischemic stroke and whether inhibitors of them could help manage stroke. It concerns stroke, not treating, curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Aljarba, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Shokr, M. M., Papadakis, M., Alexiou, A. T., et al. (2025). The possible therapeutic role of advanced glycation end-product inhibitors in ischemic stroke. Brain Research Bulletin. https://doi.org/10.1016/j.brainresbull.2025.111236

Vancouver

Aljarba NH, Al-Kuraishy HM, Al-Gareeb AI, Shokr MM, Papadakis M, Alexiou AT, et al. The possible therapeutic role of advanced glycation end-product inhibitors in ischemic stroke. Brain Research Bulletin. 2025. doi:10.1016/j.brainresbull.2025.111236. PMID: 39892578.

BibTeX

@article{aljarba2025-39892578,
  author  = {Aljarba, Nada Hamad and Al-Kuraishy, Hayder Mutter and Al-Gareeb, Ali Ismail and Shokr, Mustafa M and Papadakis, Marios and Alexiou, Athanasios T. and Alruwaili, Mubarak and Alrouji, Mohammed and others},
  title   = {{The possible therapeutic role of advanced glycation end-product inhibitors in ischemic stroke}},
  journal = {Brain Research Bulletin},
  year    = {2025},
  doi     = {10.1016/j.brainresbull.2025.111236},
  pmid    = {39892578},
  url     = {https://doi.org/10.1016/j.brainresbull.2025.111236}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses how advanced glycation end-products may contribute to ischemic stroke and whether inhibitors of them could help manage stroke. It concerns stroke, not treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Brain Research Bulletin)
Journal's citation record 2 / 4 Brain Research Bulletin: journal h-index 203 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 9 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Gaber El‐Saber Batiha: h-index 72 (OpenAlex, whole career)
Institution's track record 0 / 3 Witten/Herdecke University: institution h-index 335 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39892578)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Disease mechanisms from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →